Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as tofacitinib
CP-690-550 · 1 trial · 1 indication
ACR20 response: greater than or equal to (\>=) 20 % improvement in tender joint count (TJC); \>= 20% improvement in swollen joint count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| 7 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Adalimumab | DRUG | 40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12. |
| CP-690-550 | DRUG | 15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10) |
| CP-690,550 | DRUG | 3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10) |
| Placebo | DRUG | Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10) |
Inclusion Criteria: * Subjects must have active rheumatoid arthritis * Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD) * Subjects must not be currently taking any DMARD other than an antimalarial Exclusion Criteria: * Subjects who discontinued any previous TNF i...
CP-690-550, also known as tofacitinib, is an investigational small molecule being studied for the treatment of psoriasis, juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is in Phase 2 clinical development for these immunology indications.
CP-690-550 is a kinase inhibitor, belonging to the -tinib class of drugs. It targets kinases, which are enzymes involved in cell signaling pathways. By inhibiting these kinases, it modulates immune responses relevant to the autoimmune and inflammatory conditions it is being studied for.
CP-690-550 is being developed by Pfizer, Inc., a biopharmaceutical company. Pfizer is the sponsor of the clinical trials for this drug, which is also known as tofacitinib.
CP-690-550 is in Phase 2 clinical development for its investigational indications. It is not approved by the FDA and remains under study. The drug is being evaluated in clinical trials to assess its safety and efficacy for conditions such as rheumatoid arthritis and psoriasis.
CP-690-550 has completed four Phase 1 clinical trials, including NCT01599377, NCT02487433, NCT04111614, and NCT04403776. These trials enrolled healthy volunteers to study bioequivalence, food effects, and pharmacokinetics of different formulations. No active trials are currently listed.
Yes, CP-690-550 is also known as tofacitinib. The drug is referred to by both names in clinical research and development contexts. Pfizer is developing this compound under the name tofacitinib.